MTI BIOTECH, INC.
Biotech · Acquired
2-HOBA, a small molecule therapeutic that neutralizes reactive lipids to restore SIRT3 function and correct metabolic defects in pulmonary hypertension
- Grants
- $4.4M
- 6 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 9
- 3 granted · 6 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20192020202120222023202420252026
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase II · 2-Hydroxybenzylamine for the prevention of Alzheimer's disease: Initial evaluation in humans | $605,216 | |
| Federal grant | Department of Health and Human Services · Phase I · Efficacy of an Electrophile Scavenger in the Prevention of Gastrointestinal Inflammatory Carcinogenesis | $400,000 | |
| Federal grant | Department of Health and Human Services · Phase I · 2-HOBA for Treatment of Pulmonary Hypertension | $256,580 | |
| Federal grant | Department of Health and Human Services · Phase II · 2-HOBA for Treatment of Pulmonary Hypertension | $1,173,060 | |
| Federal grant | Department of Health and Human Services · Phase II · 2-HOBA for Treatment of Pulmonary Hypertension | $957,913 | |
| Federal grant | Department of Health and Human Services · Phase II · 2-HOBA for Treatment of Pulmonary Hypertension | $957,913 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1706 | Phoenix Nest Inc. | — | — |
| 1707 | Remedy Labs, Inc. | — | $500K |
| 1708 | STOECKER MD, WILLIAM V | — | — |
| 1709 | MTI BIOTECH, INC. | — | — |
| 1710 | GISMO THERAPEUTICS INC. | — | — |
| 1711 | SINOPIA BIOSCIENCES INC | — | — |
| 1712 | NEUROGT INC | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Compositions And Methods Of Use Of Gamma-ketoaldheyde Scavengers For Treating, Preventing Or Improving Fibrosis Of The Livergranted
- Triphenylphosphonium-tethered Salicylamine Derivativesapplication
- Compositions And Methods Of Use Of Gamma-ketoaldehyde Scavengers For Treating, Preventing Or Improving Nonalcoholic Fatty Liver Disease (nafld), Nash, Ald Or Conditions Related To The Liverapplication
- Triphenylphosphonium-tethered Salicylamine Derivativesgranted
- Compositions And Methods Of Use Of Gamma-ketoaldehyde Scavengers For Treating, Preventing Or Improving Nonalcoholic Fatty Liver Disease (nafld), Nash, Ald Or Conditions Related To The Livergranted
- Compositions And Methods Of Use Of Gamma-ketoaldheyde Scavengers For Treating, Preventing Or Improving Fibrosis Of The Liverapplication
- Triphenylphosphonium-tethered Salicylamine Derivativesapplication
- Triphenylphosphonium-tethered Salicylamine Derivativesapplication
- Compositions And Methods Of Use Of Gamma-ketoaldheyde Scavengers For Treating, Preventing Or Improving Fibrosis Of The Liverapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.